The Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that its nasopharyngeal swab and genomic toehold switch technologies have been licensed to Alabama-based Agile Biodetection. The company will use the two technologies for unmet diagnostic needs in the detection of the SARS-CoV-2 virus in environmental or clinical settings.
Motivated by the serious shortage of swab devices for the collection of nasopharyngeal samples early in the pandemic, Wyss Institute researchers created a simple and effective nasal swab device that is fully injection-molded from a single material, and as such, can be mass manufactured in a one-step process that is faster, less expensive, and routinely used by a broad range of experienced medical device manufacturers worldwide.
Conventional nasal swabs that are commonly used in infectious disease diagnostic medicine were designed 50 years ago, and are manufactured in two parts from different materials that then need to be assembled, sterilized and packaged in a multi-step process, which requires considerable time and expense. In successful tests performed by academic collaborators and teaching hospitals, the unique nasal swab design was demonstrated to effectively collect SARS-CoV-2 genetic RNA material from the nostrils of patients and to be more comfortable than existing commercial products.
Toehold switches could come into play at the other end of the COVID-19 diagnostic process. Pioneered in the groups of Wyss Core Faculty members James Collins, Ph.D., and Peng Yin, Ph.D., they are synthetic nucleic acid-based devices that function as sensors for external stimuli (“inputs”), like RNA molecules derived from pathogenic viruses. When integrated into synthetic gene circuits, Toehold Switches can be designed to turn on a gene of interest, which can be a reporter signaling the presence of the environmental stimulus. In their OFF state, these nanotechnological devices form a hairpin-like structure that specifically associates with and actively blocks the expression of a (reporter) target gene. Once an “input” RNA binds to their “toehold” region, the hairpin structure opens up and adopts an ON state to allow the protein-synthesizing machinery access to the target gene, which results in the synthesis of the actual signaling molecule.
The licensing agreement was coordinated by Harvard’s Office of Technology Development (OTD) in accordance with the University’s commitment to the COVID-19 Technology Access Framework.
Paving the way to real-world diagnostic solutions
Agile Biodetection is approaching the pandemic from an alternate viewpoint. Instead of testing patients for the virus, they’re focusing on detecting SARS-CoV-2 in the environment, including on surfaces and touchpoints within high-traffic areas. They’re applying a high-throughput cloud-based system to dissiminate the results of testing, making it faster and providing a leading indicator of the risk of infection.
“We believe that 3-pronged testing… of individuals, surfaces, and the environment, will be necessary to provide students, consumers and employees confidence to start the path back to normalcy,” said Kanti Sunkavalli, M.D., M.B.A., the CEO of Agile Biodetection.
Harvard co-led the creation of the COVID-19 Technology Access Framework, now endorsed by 23 other research institutions, to incentivize the rapid utilization of available technologies that can facilitate the diagnosis, treatment, and prevention of COVID-19 infection in the fight against the pandemic. Accordingly, the term-limited license agreement crafted by Harvard OTD grants Agile non-exclusive, royalty-free access to the Wyss nasal swab and Toehold Switch technologies for use in new SARS-CoV-2 detection approaches during the pandemic.
